Sign in

You're signed outSign in or to get full access.

Roanna

Senior Managing Director and Senior Biotechnology Analyst at Leerink Partners

Roanna Ruiz, Ph.D., is a Senior Managing Director and Senior Biotechnology Analyst at Leerink Partners, specializing in biopharma, cardiovascular, endocrine disorders, and infectious diseases. She covers specific companies including Xeris Biopharma, Akebia Therapeutics, CorMedix, Lexicon Pharmaceuticals, Vir Biotechnology, ARS Pharmaceuticals, and NewAmsterdam Pharma, with a track record featuring 71.4% buy recommendations out of 14 ratings over the last three years, though TipRanks rates her at 0.79 stars and 43.19% success rate across 25 stocks. Ruiz joined Leerink Partners in 2018 after equity research roles at UBS and H.C. Wainwright, and prior pharmaceutical consulting at IQVIA, holding a Ph.D. in Biomedical Engineering from Cornell University and a B.S. in Engineering Sciences from Harvard University.

Roanna's questions to ARDELYX (ARDX) leadership

Question · Q4 2025

Roanna asked what prescribers will focus on most regarding the primary and secondary endpoints in the Phase III CIC study, and if there is a specific efficacy bar for defining a highly successful trial.

Answer

CEO Mike Raab stated that gastroenterologists prioritize durable complete spontaneous bowel movements (CSBMs) for CIC patients, with quality of life as an important secondary endpoint. Chief Commercial Officer Eric Foster added that the goal is to show efficacy in constipation and improve overall patient quality of life, positioning IBSRELA as a needed option with a differentiated mechanism.

Ask follow-up questions

Fintool

Fintool can predict ARDELYX logo ARDX's earnings beat/miss a week before the call